Novo gains head start on Lilly with European Commission approval of Wegovy pill

In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish company got a three-month head start earlier this year, which has proven | The European Commission has granted marketing authorization for Novo Nordisk’s Wegovy pill for people with obesity or who are overweight. The approval comes as Novo’s weight-loss rival, Eli Lilly, awaits European clearance for its oral GLP-1 drug, Foundayo.